Avidity Partners 13F holdings, Q1 2023
Holdings as of March 31, 2023 · filings on SEC EDGAR · latest filing →
Avidity Partners disclosed 83 US equity positions worth $3.0bn in its Q1 2023 13F filing. The largest position was ARVN at 3.9% of the reported book, followed by SGRY and BIO. Against the Q4 2022 filing, it opened 15 new positions, added to 11 and reduced 21 among the top 50 holdings.
What did Avidity Partners own in Q1 2023? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q4 2022 |
|---|---|---|---|---|---|---|---|
| 1 | ARVN ARVINAS INC | Healthcare | 3.9% | $116.8m | 4,273,900 | -14% | reduced |
| 2 | SGRY SURGERY PARTNERS INC | Healthcare | 3.8% | $115.7m | 3,355,900 | 8% | added |
| 3 | BIO BIO RAD LABS INC | Healthcare | 3.5% | $106.1m | 221,500 | 140% | added |
| 4 | ARGX ARGENX SE | Healthcare | 3.5% | $104.6m | 280,700 | -55% | reduced |
| 5 | JAZZ JAZZ PHARMACEUTICALS PLC | Healthcare | 3.3% | $99.2m | 677,900 | -7% | reduced |
| 6 | REGN REGENERON PHARMACEUTICALS | Healthcare | 3.2% | $97.9m | 119,100 | – | new |
| 7 | AKERO THERAPEUTICS INC | 3.1% | $93.6m | 2,447,000 | -36% | reduced | |
| 8 | THC TENET HEALTHCARE CORP | Healthcare | 2.9% | $87.5m | 1,472,000 | 105% | added |
| 9 | RARE ULTRAGENYX PHARMACEUTICAL IN | Healthcare | 2.8% | $85.3m | 2,126,900 | -29% | reduced |
| 10 | UHS UNIVERSAL HLTH SVCS INC | Healthcare | 2.8% | $85.2m | 670,000 | -19% | reduced |
| 11 | ACHC ACADIA HEALTHCARE COMPANY IN | Healthcare | 2.8% | $84.2m | 1,165,300 | 0% | held |
| 12 | NBIX NEUROCRINE BIOSCIENCES INC | Healthcare | 2.7% | $82.6m | 815,700 | -54% | reduced |
| 13 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 2.7% | $81.6m | 3,865,300 | -34% | reduced |
| 14 | KARUNA THERAPEUTICS INC | 2.4% | $73.3m | 403,800 | 35% | added | |
| 15 | BDX BECTON DICKINSON & CO | Healthcare | 2.4% | $71.3m | 288,000 | – | new |
| 16 | PLRX PLIANT THERAPEUTICS INC | Healthcare | 2.4% | $70.9m | 2,665,000 | 19% | added |
| 17 | ZTS ZOETIS INC | Healthcare | 2.3% | $67.8m | 407,500 | – | new |
| 18 | VENTYX BIOSCIENCES INC | 2.1% | $64.2m | 1,917,800 | 49% | added | |
| 19 | MRK MERCK & CO INC | Healthcare | 2.1% | $63.8m | 600,000 | – | new |
| 20 | SRPT SAREPTA THERAPEUTICS INC | Healthcare | 1.9% | $57.3m | 416,000 | -61% | reduced |
| 21 | LEGN LEGEND BIOTECH CORP | Healthcare | 1.8% | $54.0m | 1,120,500 | 16% | added |
| 22 | PROTHENA CORP PLC | 1.7% | $51.8m | 1,068,200 | -64% | reduced | |
| 23 | IDYA IDEAYA BIOSCIENCES INC | Healthcare | 1.7% | $50.4m | 3,673,400 | -4% | reduced |
| 24 | ZNTL ZENTALIS PHARMACEUTICALS INC | Healthcare | 1.7% | $50.4m | 2,929,300 | -43% | reduced |
| 25 | IVERIC BIO INC | 1.5% | $45.5m | 1,869,200 | 123% | added | |
| 26 | ARWR ARROWHEAD PHARMACEUTICALS IN | Healthcare | 1.5% | $44.2m | 1,741,300 | 27% | added |
| 27 | PACB PACIFIC BIOSCIENCES CALIF IN | Healthcare | 1.5% | $44.1m | 3,812,600 | – | new |
| 28 | BSX BOSTON SCIENTIFIC CORP | Healthcare | 1.4% | $42.5m | 850,000 | -74% | reduced |
| 29 | AXSM AXSOME THERAPEUTICS INC | Healthcare | 1.3% | $38.2m | 619,200 | -8% | reduced |
| 30 | VIR VIR BIOTECHNOLOGY INC | Healthcare | 1.3% | $38.2m | 1,640,200 | 93% | added |
| 31 | IMCR IMMUNOCORE HLDGS PLC | Healthcare | 1.3% | $38.1m | 769,800 | -33% | reduced |
| 32 | KPTI KARYOPHARM THERAPEUTICS INC | Healthcare | 1.2% | $37.5m | 9,633,911 | 0% | held |
| 33 | ABT ABBOTT LABS | Healthcare | 1.2% | $35.8m | 354,000 | – | new |
| 34 | BIIB BIOGEN INC | Healthcare | 1.2% | $35.8m | 128,800 | – | new |
| 35 | BELLUS HEALTH INC NEW | 1.1% | $32.8m | 4,553,577 | -1% | reduced | |
| 36 | ICLR ICON PLC | Healthcare | 1.0% | $30.5m | 142,900 | -34% | reduced |
| 37 | BMRN BIOMARIN PHARMACEUTICAL INC | Healthcare | 1.0% | $29.2m | 300,575 | – | new |
| 38 | RVMD REVOLUTION MEDICINES INC | Healthcare | 1.0% | $29.1m | 1,344,800 | -46% | reduced |
| 39 | 89BIO INC | 0.9% | $28.1m | 1,842,976 | – | new | |
| 40 | AMLX AMYLYX PHARMACEUTICALS INC | Healthcare | 0.9% | $26.4m | 900,000 | – | new |
| 41 | CUREVAC N V | 0.8% | $24.7m | 3,550,000 | – | new | |
| 42 | AVTR AVANTOR INC | Healthcare | 0.8% | $23.8m | 1,125,000 | – | new |
| 43 | NANOSTRING TECHNOLOGIES INC | 0.7% | $21.9m | 2,217,000 | 8% | added | |
| 44 | FUSION PHARMACEUTICALS INC | 0.7% | $21.5m | 5,700,000 | – | new | |
| 45 | RCKT ROCKET PHARMACEUTICALS INC | Healthcare | 0.7% | $21.3m | 1,244,400 | -19% | reduced |
| 46 | KEZAR LIFE SCIENCES INC | 0.7% | $20.4m | 6,519,400 | -4% | reduced | |
| 47 | BHVN BIOHAVEN LTD | Healthcare | 0.7% | $20.3m | 1,487,200 | -0% | held |
| 48 | COR AMERISOURCEBERGEN CORP | Healthcare | 0.7% | $20.3m | 126,600 | – | new |
| 49 | MLYS MINERALYS THERAPEUTICS INC | Healthcare | 0.7% | $19.8m | 1,263,800 | – | new |
| 50 | VERVE THERAPEUTICS INC | 0.6% | $19.5m | 1,351,700 | -14% | reduced |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.